0439 GMT - Healthcare software provider Mach7 Technologies looks well-positioned to meet its annual guidance, according to its bull at Wilsons. Analyst Shane Storey tells clients in a note that the Australia-listed company needs to sign more new accounts in its June quarter, but still forecasts 19% annual growth in full-year contracted annual recurring revenue. That's well within Mach7's guidance of 15%-25%. Mach7 is positioned to sustainably generate operating cashflow from hereon, with its cost-cutting initiatives completed in the March quarter, Storey adds. Wilsons cuts its target price by 15% to A$0.85 and keeps an overweight rating on the stock, which is up 7.8% at A$0.345. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 00:39 ET (04:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。